Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. What is Retatrutide? Retatrutide is a notable triple-agonist peptide, which means it targets three different hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and …